Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Dabrafenib Alters MDSC Differentiation and Function by Activation of GCN2
M. Teresa Ciudad
, Rene Quevedo
, Sara Lamorte
, Robbie Jin
, Nadine Nzirorera
, Marianne Koritzinsky
, Tracy L. McGaha
Research output
:
Contribution to journal
›
Article
›
peer-review
9
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dabrafenib Alters MDSC Differentiation and Function by Activation of GCN2'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cell Function
100%
Cell Differentiation
100%
Trametinib
100%
GCN2
100%
Monocytic Myeloid-derived Suppressor Cells (M-MDSCs)
100%
Cell Development
30%
Polymorphonuclear MDSC
30%
Targeted Therapeutics
20%
Monocytic
20%
Transcriptional Program
20%
BRAF Inhibitor (BRAFi)
20%
Off-target Effects
20%
Transcriptional Network
20%
Integrated Stress Response
20%
Tumor
10%
T Cell Activation
10%
Tumor Growth
10%
Cell Population
10%
Therapeutic Effect
10%
Pathway Activity
10%
Tumor-bearing Mice
10%
Innate Immune Response
10%
Developmental Pathways
10%
Cell Loss
10%
Stress Signaling
10%
Transcriptional Profiling
10%
Anticancer Immune Response
10%
Novel Therapeutic Targets
10%
Antitumor Immune Response
10%
Increased Activity
10%
Therapeutic Combinations
10%
Tumor-infiltrating Immune Cells
10%
Developmental Arrest
10%
Regulon
10%
Development Program
10%
MafG
10%
Proliferative Arrest
10%
ZBTB7A
10%
Immune Landscape
10%
ATF5
10%
Oxidative Respiration
10%
Suppressive Activity
10%
Metabolic Features
10%
Immunology and Microbiology
Myeloid
100%
Cell Differentiation
100%
Myeloid-Derived Suppressor Cell
100%
Cell Maturation
37%
Cell Function
25%
Immune Response
25%
Phosphotransferase
25%
Kinase
25%
T Cell
12%
Cell Population
12%
Gene Expression Assay
12%
Lineage
12%
Downregulation
12%
Cell Loss
12%
Cell Activity
12%
Regulon
12%
Immune Landscape
12%
In Vitro
12%
Therapeutic Target
12%